The Association of American Physicians and Surgeons Educational Foundation Challenges Censorship
18. Dezember 2023 12:55 ET
|
Association of American Physicians and Surgeons
AAPS Educational Foundation challenges censorship imposed by revoking physicians' board certification, and the Biden regime's Disinformation board.
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
09. Mai 2022 07:00 ET
|
ObsEva SA
-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
09. Mai 2022 01:00 ET
|
ObsEva SA
-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...
The Joint Commission and the American College of Obstetricians and Gynecologists announce new collaboration to address maternal health
23. Juni 2021 11:30 ET
|
Joint Commission
OAKBROOK TERRACE, Ill., June 23, 2021 (GLOBE NEWSWIRE) -- The Joint Commission and the American College of Obstetricians and Gynecologists (ACOG) today announced a new collaboration to help reduce...
Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations
25. Mai 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business...
Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results
13. Mai 2021 16:03 ET
|
Progenity, Inc.
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with...
Progenity Provides Key Update Regarding its Preecludia™ Test for Preeclampsia
05. Mai 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
30. April 2021 16:05 ET
|
ObsEva SA
GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
30. April 2021 16:04 ET
|
Progenity, Inc.
SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting
30. April 2021 11:01 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial...